CLPT — Clearpoint Neuro Income Statement
0.000.00%
Last trade - 00:00- $411.30m
- $391.20m
- $31.39m
Annual income statement for Clearpoint Neuro, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 12.8 | 16.3 | 20.6 | 24 | 31.4 |
| Cost of Revenue | |||||
| Gross Profit | 9.12 | 11.3 | 13.5 | 13.6 | 19.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 19 | 29.7 | 36.9 | 46.4 | 51.1 |
| Operating Profit | -6.22 | -13.4 | -16.3 | -22.4 | -19.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.78 | -14.4 | -16.4 | -22.1 | -18.9 |
| Net Income After Taxes | -6.78 | -14.4 | -16.4 | -22.1 | -18.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.78 | -14.4 | -16.4 | -22.1 | -18.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.78 | -14.4 | -16.4 | -22.1 | -18.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.422 | -0.695 | -0.68 | -0.898 | -0.7 |